Ann: Anti-Infective Portfolio Update and Webinar details, page-14

Agreed - is the Phase I still progressing or have they stopped dosing? Even with higher doses, it's difficult to see that they would be able to get sufficient plasma concentrations to kill planktonic bacteria. In saying that, it looks as though R327 can partially disrupt bacterial metabolism and viability at these lower ppm concentrations based on their ATP assays. I don't know the answer, but this might prevent bacterial proliferation to an extent, giving the host immune response more time to correct and return to homeostasis in the case of sepsis. Of course, this would all depend on what the host contributes towards bacterial virulence in vivo. Furthermore, there may be a case for combination of R327 with other antibiotics at lower doses to produce a synergistic effect.

I was also quite interested in their biofilm data. I'm assuming 1x is the concetration of the drug product in the bottle?

I've said in the past that the PK data would be one of the most important aspects of the Phase I trial. Makes sense why they're now looking towards UTIs, given that they're seeing around 2000 ppm in urine at 6000 mg dose.

Topical and UTI markets are still massive opportunities though, so i wouldn't be too worried at this point (at least not anymore than you should be with a speculative biotech!).